TENX - Tenax Therapeutics to Host KOL Event: LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF and the Ongoing Phase 3 LEVEL Study | Benzinga
Panel of renowned cardiologists, all globally recognized experts in heart failure, will discuss the unmet medical need in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) and the potential role for levosimendan in treating this prevalent, fatal disease
Experts will explain pathophysiology of PH-HFpEF, and mechanistic rationale for levosimendan
Update on the ongoing Phase 3 LEVEL Study evaluating TNX-103 (oral levosimendan) for the treatment of PH-HFpEF
Tenax to Host Webcast on Thursday, April 18, 2024, at 10:00 am ET
CHAPEL HILL, N.C., April 09, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that Stuart Rich, Tenax CMO, will moderate "LEVEL Setting," a scientific round-table exploration of the rationale for TNX-103 (oral levosimendan), for the treatment of PH-HFpEF.
Presentations from four globally recognized experts in the field of heart failure will explore this most prevalent type of pulmonary hypertension and the therapeutic potential of levosimendan:
- Understanding the setting of PH-HFpEF – Sanjiv Shah, M.D. (Northwestern University)
- Mechanism of Action of Levosimendan – Daniel Burkhoff, M.D., Ph.D. (Columbia)
- Review of data from the Phase 2 HELP Study – Barry Borlaug, M.D. (Mayo Clinic)
- Current treatment landscape in PH-HFpEF – Javed Butler, M.D., M.P.H., M.B.A. (Baylor Scott & White)
Following the seminar, members of Tenax Therapeutics senior management will provide a brief update on the ongoing Phase 3 LEVEL Study, followed by a Q&A session with the experts.
To register for the event, please click here.
KOL Biographies
Sanjiv Shah, M.D.
Dr. Sanjiv Shah is the Stone Endowed Professor of Medicine, Director of Research for the Bluhm Cardiovascular Institute, and Director of the HFpEF Program at Northwestern University Feinberg School of Medicine. His clinical expertise is in HFpEF, pulmonary hypertension, echocardiography, hemodynamics, and rare cardiomyopathies such as cardiac amyloidosis. Dr. Shah's research interests include understanding the physiology, mechanisms, epidemiology, and treatment of HFpEF. He started the first dedicated HFpEF clinical program in the world at Northwestern University in 2007, now a model for programs around the world, and has been the overall principal investigator or on the steering committee/executive committee of > 35 multicenter, randomized HF clinical trials. His research interests also include the study of acquired and genetic risk factors for abnormal cardiac mechanics, and novel machine learning techniques for improved classification and therapeutic targeting for HF syndromes. Dr. Shah is currently the PI of multiple active NIH R01 grants and an AHA Strategically Focused Research Network project grant. Dr. Shah has published over 355 peer-reviewed research publications, and he is an Associate Editor for JAMA Cardiology.
Daniel Burkhoff, M.D., Ph.D.
Dr. Burkhoff obtained Doctor of Philosophy and Medical degrees from The Johns Hopkins School of Medicine and completed a fellowship in Cardiology at The Johns Hopkins Hospital. Dr. Burkhoff then moved to Columbia University in the City of New York where he established and ran the Cardiovascular Research Laboratory through 2003 and then took the position of Director ...